121 related articles for article (PubMed ID: 11148457)
1. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features.
Horie S; Maeta H; Endo K; Ueta T; Takashima K; Terada T
Pathol Int; 2001 Jan; 51(1):11-5. PubMed ID: 11148457
[TBL] [Abstract][Full Text] [Related]
2. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
3. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
4. Expression of mdm2 and p53 in epithelial neoplasms of the colorectum.
Hao XP; Günther T; Roessner A; Price AB; Talbot IC
Mol Pathol; 1998 Feb; 51(1):26-9. PubMed ID: 9624416
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of p53 protein expression in papillary thyroid carcinoma.
Morita N; Ikeda Y; Takami H
World J Surg; 2008 Dec; 32(12):2617-22. PubMed ID: 18836853
[TBL] [Abstract][Full Text] [Related]
6. P53 and MDM2 Over-expression and Five-year Survival of Kidney Cancer Patients Undergoing Radical Nephrectomy--Iranian Experience.
Abolhasani M; Salarinejad S; Asgari M
Asian Pac J Cancer Prev; 2015; 16(12):5043-7. PubMed ID: 26163638
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions.
Martins MB; de Assis Batista F; Marcello MA; Bufalo NE; Peres KC; Morari EC; Soares FA; Vassallo J; Ward LS
Ann Diagn Pathol; 2021 Aug; 53():151766. PubMed ID: 34111705
[TBL] [Abstract][Full Text] [Related]
8. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
10. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma.
Shin MK; Kim JW
Asian Pac J Cancer Prev; 2014; 15(5):2341-4. PubMed ID: 24716981
[TBL] [Abstract][Full Text] [Related]
12. Co-overexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and clinicopathologic stage.
Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H
Int J Oncol; 1999 Nov; 15(5):893-8. PubMed ID: 10536170
[TBL] [Abstract][Full Text] [Related]
13. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
15. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter.
Hashimoto H; Sue Y; Saga Y; Tokumitsu M; Yachiku S
Int J Urol; 2000 Dec; 7(12):457-63. PubMed ID: 11168685
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications.
Omar E; Madhavan M; Othman NH
Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751
[TBL] [Abstract][Full Text] [Related]
17. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
18. No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis.
Blok P; Craanen ME; Dekker W; Offerhaus GJ; Tytgat GN
J Pathol; 1998 Sep; 186(1):36-40. PubMed ID: 9875138
[TBL] [Abstract][Full Text] [Related]
19. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.
Emanuels AG; Koudstaal J; Burger MP; Hollema H
Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975
[TBL] [Abstract][Full Text] [Related]
20. MDM2 expression in areca quid chewing-associated oral squamous cell carcinomas in Taiwan.
Huang JS; Ho TJ; Chiang CP; Kok SH; Kuo YS; Kuo MY
J Oral Pathol Med; 2001 Jan; 30(1):53-8. PubMed ID: 11140901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
